中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
3期
459-460
,共2页
莲芪胶囊%肝动脉栓塞化疗%原发性肝癌
蓮芪膠囊%肝動脈栓塞化療%原髮性肝癌
련기효낭%간동맥전새화료%원발성간암
Lianqi capsules%Transcatheter hepatic arterial chemoembolization%Primary liver cancer
目的：探讨莲芪胶囊联合肝动脉栓塞化疗治疗原发性肝癌的临床疗效。方法：98例原发性肝癌患者,随机分为治疗组和对照组,各49例,两组均行肝动脉栓塞化疗,治疗组加服莲芪胶囊,对照组加服平消胶囊。结果：治疗组治疗后临床症状积分较对照组显著降低(P<0.05),KPS积分、CD4+、CD4+/CD8+比值、NK细胞数量较对照组显著升高(P<0.05)。结论：莲芪胶囊能增强原发性肝癌患者免疫功能,有效改善患者临床症状。
目的：探討蓮芪膠囊聯閤肝動脈栓塞化療治療原髮性肝癌的臨床療效。方法：98例原髮性肝癌患者,隨機分為治療組和對照組,各49例,兩組均行肝動脈栓塞化療,治療組加服蓮芪膠囊,對照組加服平消膠囊。結果：治療組治療後臨床癥狀積分較對照組顯著降低(P<0.05),KPS積分、CD4+、CD4+/CD8+比值、NK細胞數量較對照組顯著升高(P<0.05)。結論：蓮芪膠囊能增彊原髮性肝癌患者免疫功能,有效改善患者臨床癥狀。
목적：탐토련기효낭연합간동맥전새화료치료원발성간암적림상료효。방법：98례원발성간암환자,수궤분위치료조화대조조,각49례,량조균행간동맥전새화료,치료조가복련기효낭,대조조가복평소효낭。결과：치료조치료후림상증상적분교대조조현저강저(P<0.05),KPS적분、CD4+、CD4+/CD8+비치、NK세포수량교대조조현저승고(P<0.05)。결론：련기효낭능증강원발성간암환자면역공능,유효개선환자림상증상。
Objective:To observe the efficacy of Lianqi combined with transcatheter hepatic arterial chemoembolization in treatment of primary liver cancer. Methods:98 patients with primary liver cancer in the hospital from January 2010 to October 2012 were divided into treatment group and control group randomly. Both groups were given transcatheter hepatic arterial chemoembolization. 49 cases in the treatment group were given additional Lianqi, while the control group were given additional Ping Xiao capsules. Results:The clinical symptom score of the treatment was significantly lower than the control group after treatment(P<0.05), while the KPS, CD4+,CD4+/CD8+ratio, NK cells were significantly higher than the control group(P<0.05).Conclusion:Lianqi could not only enhance the immune function in patients with primary liver cancer, but could also improve the clinical symptoms effectively.
